Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma

Leuk Lymphoma. 2014 May;55(5):1191-3. doi: 10.3109/10428194.2013.820289. Epub 2013 Aug 13.

Authors

Giuseppe Mele¹, Alessandro Spina, Gianluca Guaragna, Angela Giannotta, Angela Melpignano, Gianni Quarta

Affiliation

¹ Clinical Division of Haematology and BMT Unit; "Antonio Perrino" Hospital , Brindisi , Italy.

PMID: 23829305
DOI: 10.3109/10428194.2013.820289

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bendamustine Hydrochloride
Boronic Acids / administration & dosage
Bortezomib
Dexamethasone / administration & dosage
Humans
Lenalidomide
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology*
Nitrogen Mustard Compounds / administration & dosage
Pyrazines / administration & dosage
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives
Treatment Outcome

Substances

Boronic Acids
Nitrogen Mustard Compounds
Pyrazines
Thalidomide
Bortezomib
Dexamethasone
Bendamustine Hydrochloride
Lenalidomide